Moclobemide vs. imipramine in bipolar depression: a multicentre double‐blindclinical trial

@article{Silverstone2001MoclobemideVI,
  title={Moclobemide vs. imipramine in bipolar depression: a multicentre double‐blindclinical trial},
  author={Trevor Silverstone},
  journal={Acta Psychiatrica Scandinavica},
  year={2001},
  volume={104}
}
  • T. Silverstone
  • Published 2001
  • Psychology, Medicine
  • Acta Psychiatrica Scandinavica
OBJECTIVE To determine the relative efficacy, tolerability and risk of precipitating mania of moclobemide and imipramine in the treatment of bipolar depression. METHOD A randomized, double-blind, parallel group, multicentre study of moclobemide (MCB) (450-750 mg daily) and imipramine (IMI) (150-250 mg daily) in 21 centres in nine countries; 156 patients (65 males, 91 females) aged 18-65 with bipolar depression (17-item Hamilton Depression Rating Scale (HAMD) score chi16) participated… Expand
Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.
TLDR
Results of this small trial suggest that both lamotrigine and citalopram appear to be reasonable choices as add-on acute treatment for bipolar depression, with response rates continuing to rise considerably past 6 weeks of treatment. Expand
Efficacy of Tranylcypromine in Bipolar Depression: A Systematic Review
TLDR
This systematic review provides evidence for the efficacy and safety of tranylcypromine treatment in bipolar depression and establishes the efficacy of the monoamine oxidase inhibitor as add-on to a mood stabilizer. Expand
Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?
TLDR
In these patients with bipolar depression, the antidepressant effectiveness of PAROX was unacceptably low, but rates of recovery with MAOIs were significantly higher. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Treatment of Bipolar Depression, a Review of the Literature and a Suggestion for an Algorithm
TLDR
There are indications that the combined treatment of a mood stabilizer and an antidepressant (TCA) is associated with an increased risk of switches into (hypo)mania, when compared to a Mood stabilizer alone, and it is recommended to try whether a monotherapy with a mood stabilizeizer is effective, before combining it with an antidepressant. Expand
Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
TLDR
Variability in efficacy exists between treatments of bipolar depression, and quetiapine and the olanzapine-fluoxetine combination showed the greatest symptomatic improvement. Expand
Pharmacological Treatment of Bipolar Depression: Qualitative Systematic Review of Double-Blind Randomized Clinical Trials
TLDR
A systematic review covering the last 20 years was performed on PubMed selecting double-blind RCTs for bipolar depression, finding several limitations which hinder the extrapolation of the data to clinical practice. Expand
Indução de mania durante o tratamento com antidepressivos no transtorno bipolar
OBJECTIVES: To review the literature on antidepressant-induced mania, its incidence, clinical presentation, risk factors and treatment. METHODS: A Medline search of studies published between 1970 andExpand
Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder
TLDR
The authors conclude that the real question is not whether ADs should or should not be used in bipolar depression, but which patients benefit from these drugs and which ones are impaired. Expand
Reevaluating therapies for bipolar depression.
  • H. Grunze
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2005
TLDR
The efficacy and safety of antidepressants for bipolar depression both as monotherapy and when combined with a mood stabilizer should be studied in adequately powered trials in order to revise treatment guidelines. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Moclobemide versus imipramine in depressed out‐patients: a double‐blind multi‐centre study
TLDR
The decrease of the total scores of the Hamilton Depression Scale (HDRS) as well as the Overall Assessment of Efficacy by the Investigators showed significant amelioration of depression in both treatment groups, and no significant differences were found between the moclobemide and imipramine groups with regard to treatment outcome. Expand
A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder
TLDR
Tolerability was least on imipramine, largely due to the high frequency of anticholinergic side effects; moclobemide showed no difference from placebo in this respect. Expand
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine. Expand
Tranylcypromine versus imipramine in anergic bipolar depression.
TLDR
These findings provide further documentation of the utility of MAOIs in patients presenting with anergia, motor retardation, hyperphagia, and/or hypersomnia and propose that the apparently superior efficacy of tranylcypromine in bipolar depression is specifically linked to anergIA and reversed neurovegetative symptoms. Expand
Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a majorExpand
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.
TLDR
Lamotrigine monotherapy is an effective and well-tolerated treatment for bipolar depression and demonstrates significant antidepressant efficacy on the 17-item Hamilton Rating Scale for Depression, MADRS, CGI-S, and CGI-I compared with placebo. Expand
A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder.
TLDR
This was a 6-week, double-blind comparison of fluoxetine, imipramine, and placebo in 89 patients with bipolar depression, and endpoint analysis showed 86% of the fluoxettine-treated patients improved. Expand
Controlled trials in bipolar I depression: focus on switch rates and efficacy
TLDR
The low switching rates observed in these studies of lamotrigine, paroxetine and moclobemide may indicate a special application of these drugs in the management of patients prone to antidepressant-induced switching, and confirmation that tricyclic antidepressants present the highest risk of switching. Expand
Treatment of depression in bipolar disorder: new directions for research.
TLDR
There are few studies of treatment of the depressed phase of bipolar disorder, and their results generally are limited or inconclusive, but limited data on other antidepressant classes suggest that monoamine oxidase inhibitors, bupropion, and serotonergic agents may offer some advantages over tricyclic antidepressants in this population. Expand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
...
1
2
3
...